» Articles » PMID: 10090114

Corticosteroid Requirements in Polymyalgia Rheumatica

Overview
Journal Arch Intern Med
Specialty General Medicine
Date 1999 Mar 25
PMID 10090114
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Polymyalgia rheumatica (PMR) is a systemic inflammatory disease of unknown cause that affects older individuals. Clinical symptoms respond promptly to corticosteroids, but treatment is often required for several years, frequently resulting in adverse drug effects. Guidelines for the optimal use of corticosteroids that maximize relief of symptoms but minimize adverse effects of the therapy are needed.

Objective: To determine whether clinical or laboratory parameters in PMR could be identified that allow for stratifying patients into subsets with differences in corticosteroid requirements.

Patients And Methods: We studied 27 patients with PMR treated with a standardized schedule of prednisone. Patients were reevaluated at monthly intervals for pain scores and physician and patient assessments. Plasma interleukin 6 level and the erythrocyte sedimentation rate were measured at each visit. The duration of steroid therapy and the cumulative steroid dose were calculated.

Results: Based on the initial response to therapy and the duration of disease, the 27 patients could be subdivided into 3 distinct groups. Eight with low erythrocyte sedimentation rates responded rapidly and required corticosteroids for less than 1 year with rare disease flares on tapering of prednisone. Twelve others responded well initially but did not tolerate reduction to lower doses and had remitting disease of more than 1 year. Seven patients had only a partial response to the initial steroid regimen. After 4 weeks of therapy, the erythrocyte sedimentation rates improved, but levels of interleukin 6 remained elevated. Pretreatment pain scores were also higher in these partial responder patients (P = .05).

Conclusions: Polymyalgia rheumatica is a heterogeneous disease with variations in the treatment duration and dose of corticosteroids required for suppression of symptoms. Pretreatment erythrocyte sedimentation rate and nonresponsiveness of interleukin 6 to steroid therapy are helpful in dividing patients into subsets with different treatment requirements.

Citing Articles

Predictors of complete 24-month remission and flare in patients with polymyalgia rheumatica.

Perricone C, Cafaro G, Fiumicelli E, Bursi R, Bogdanos D, Riccucci I Clin Exp Med. 2022; 23(7):3391-3397.

PMID: 36566303 DOI: 10.1007/s10238-022-00976-0.


Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis.

Floris A, Piga M, Chessa E, Congia M, Erre G, Angioni M Clin Rheumatol. 2021; 41(1):19-31.

PMID: 34415462 PMC: 8724087. DOI: 10.1007/s10067-021-05819-z.


Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis.

Smutny T, Barvik I, Veleta T, Pavek P, Soukup T J Clin Med. 2019; 8(5).

PMID: 31035618 PMC: 6572549. DOI: 10.3390/jcm8050582.


Prescribing for polymyalgia rheumatica.

Liew D, Owen C, Buchanan R Aust Prescr. 2018; 41(1):14-19.

PMID: 29507455 PMC: 5828929. DOI: 10.18773/austprescr.2018.001.


Relapse of polymyalgia rheumatica after a fall.

Manzo C, Natale M Reumatologia. 2018; 55(5):251-255.

PMID: 29332964 PMC: 5746636. DOI: 10.5114/reum.2017.71642.